Revolution Medicines at AMP 2026
Nov 10–14, 2026 Seattle, WA ~2k attendees Website
Revolution Medicines brings 2 presentations to AMP 2026 in Seattle, and exhibits at Booth 528. Its sessions centre on RAS-driven cancer, tracing a mutation into a targeted drug class, and on molecular diagnostics for pancreatic lesions that are hard to see and harder to treat. The company develops oral RAS inhibitors.
| Organization | AMP 2026 Attendance |
|---|---|
Revolution Medicines Redwood City, CA | |
Oncology company developing oral RAS(ON) inhibitors for patients with RAS-addicted cancers. | Booth Exhibiting at Booth 528 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm Workshop Wed, Nov 11 3:00pm–3:50pm RAS in ACTION - From A Single Mutation to a Targeted Class RAS mutation testing across lung, colorectal and pancreatic cancers, with tissue and liquid biopsy considerations for targeted therapy. Workshop Thu, Nov 12 4:25pm–4:55pm It's Hard to Treat What You Can't See: Leveraging Molecular Diagnostics to Improve Care of Patients with Pancreatic Lesions Pancreatic lesions are hard to call on imaging and cytology alone; molecular testing can sharpen diagnosis and risk stratification. |
Instantly find 20 buyers from Revolution Medicines
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with the Association for Molecular Pathology. Organization details are derived from AMP’s published lists. Submit a correction